{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T09:34:00Z","timestamp":1767864840763,"version":"3.49.0"},"reference-count":63,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1097\/hcr.0b013e318192754e","type":"journal-article","created":{"date-parts":[[2013,9,17]],"date-time":"2013-09-17T07:39:25Z","timestamp":1379403565000},"page":"2-12","source":"Crossref","is-referenced-by-count":44,"title":["A Review of Lipid Management in Primary and Secondary Prevention"],"prefix":"10.1097","volume":"29","author":[{"given":"Ewa","family":"Dembowski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael H.","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"9524","key":"R1-2-20210128","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/S0140-6736(06)68770-9","article-title":"Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data.","volume":"367","author":"Lopez","year":"2006","journal-title":"Lancet"},{"key":"R2-2-20210128","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"R3-2-20210128","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"R4-2-20210128","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1161\/01.CIR.97.18.1837","article-title":"Prediction of coronary heart disease using risk factor categories.","volume":"97","author":"Wilson","year":"1998","journal-title":"Circulation"},{"key":"R5-2-20210128","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1001\/jama.1986.03380200061022","article-title":"Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT).","volume":"256","author":"Stamler","year":"1986","journal-title":"JAMA"},{"key":"R6-2-20210128","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jama.1984.03340270029025","article-title":"Trial results; part I: reduction in incidence of coronary heart disease.","volume":"251","year":"1984","journal-title":"JAMA"},{"key":"R7-2-20210128","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1001\/jama.1984.03340270043026","article-title":"Trial results; part II: the relationship of reduction in incidence of coronary heart disease to cholesterol lowering.","volume":"251","year":"1984","journal-title":"JAMA"},{"key":"R8-2-20210128","doi-asserted-by":"crossref","first-page":"687","DOI":"10.7326\/0003-4819-115-9-687","article-title":"Serum cholesterol as a prognostic factor after myocardial infarction: the Framingham Study.","volume":"115","author":"Wong","year":"1991","journal-title":"Ann Intern Med"},{"key":"R9-2-20210128","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1056\/NEJM199006143222403","article-title":"Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease.","volume":"322","author":"Pekkanen","year":"1990","journal-title":"N Engl J Med"},{"key":"R10-2-20210128","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ijcard.2005.08.034","article-title":"Effect of a low-carbohydrate, ketogenic diet program compared to a low-fat diet on fasting lipoprotein subclasses.","volume":"110","author":"Westman","year":"2006","journal-title":"Int J Cardiol"},{"key":"R11-2-20210128","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.2337\/diabetes.54.5.1566","article-title":"Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance.","volume":"54","author":"Haffner","year":"2005","journal-title":"Diabetes"},{"issue":"8911","key":"R12-2-20210128","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S0140-6736(94)92580-1","article-title":"Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease.","volume":"343","author":"de Lorgeril","year":"1994","journal-title":"Lancet"},{"key":"R13-2-20210128","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0002-9149(03)00530-7","article-title":"Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial).","volume":"92","author":"Jones","year":"2003","journal-title":"Am J Cardiol"},{"issue":"5A","key":"R14-2-20210128","doi-asserted-by":"crossref","first-page":"24F","DOI":"10.1016\/j.amjcard.2005.06.009","article-title":"Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol.","volume":"96","author":"Liao","year":"2005","journal-title":"Am J Cardiol"},{"issue":"8934","key":"R15-2-20210128","first-page":"1383","article-title":"4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"R16-2-20210128","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators.","volume":"335","author":"Sacks","year":"1996","journal-title":"N Engl J Med"},{"key":"R17-2-20210128","first-page":"1349","article-title":"The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group.","volume":"339","year":"1998","journal-title":"N Engl J Med"},{"key":"R18-2-20210128","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease.","volume":"352","author":"LaRosa","year":"2005","journal-title":"N Engl J Med"},{"issue":"9326","key":"R19-2-20210128","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"R20-2-20210128","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1016\/j.jacc.2004.03.046","article-title":"Optimal low-density lipoprotein is 50 to 70 mg\/dl: lower is better and physiologically normal.","volume":"43","author":"OKeefe","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"R21-2-20210128","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1001\/jama.294.19.2437","article-title":"High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.","volume":"294","author":"Pedersen","year":"2005","journal-title":"JAMA"},{"key":"R22-2-20210128","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.","volume":"333","author":"Shepherd","year":"1995","journal-title":"N Engl J Med"},{"key":"R23-2-20210128","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention Study.","volume":"279","author":"Downs","year":"1998","journal-title":"JAMA"},{"issue":"9346","key":"R24-2-20210128","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","article-title":"Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial.","volume":"360","author":"Shepherd","year":"2002","journal-title":"Lancet"},{"key":"R25-2-20210128","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1001\/jama.288.23.2998","article-title":"Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).","volume":"288","year":"2002","journal-title":"JAMA"},{"issue":"9364","key":"R26-2-20210128","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","article-title":"Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.","volume":"361","author":"Sever","year":"2003","journal-title":"Lancet"},{"issue":"9493","key":"R27-2-20210128","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"issue":"9539","key":"R28-2-20210128","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0140-6736(06)69292-1","article-title":"Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study.","volume":"368","author":"Deedwania","year":"2006","journal-title":"Lancet"},{"issue":"9435","key":"R29-2-20210128","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"issue":"suppl 1","key":"R30-2-20210128","first-page":"S12","article-title":"Standards of medical care in diabetes-2008.","volume":"31","year":"2008","journal-title":"Diab Care"},{"key":"R31-2-20210128","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1046\/j.0306-5251.2001.01478.x","article-title":"Statins for primary prevention: at what coronary risk is safety assured?","volume":"52","author":"Jackson","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"R32-2-20210128","doi-asserted-by":"crossref","first-page":"326","DOI":"10.7326\/0003-4819-144-5-200603070-00007","article-title":"Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis.","volume":"144","author":"Pignone","year":"2006","journal-title":"Ann Intern Med"},{"issue":"23","key":"R33-2-20210128","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1161\/CIRCULATIONAHA.107.713438","article-title":"Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment.","volume":"117","author":"Kastelein","year":"2008","journal-title":"Circulation"},{"key":"R34-2-20210128","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1161\/01.CIR.0000038419.53000.D6","article-title":"Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy.","volume":"106","author":"Grundy","year":"2002","journal-title":"Circulation"},{"key":"R35-2-20210128","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1515\/CCLM.2004.254","article-title":"The apoB\/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk.","volume":"42","author":"Walldius","year":"2004","journal-title":"Clin Chem Lab Med"},{"key":"R36-2-20210128","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0009-9120(01)00263-6","article-title":"The plasma parameter log (TG\/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)).","volume":"34","author":"Dobiasova","year":"2001","journal-title":"Clin Biochem"},{"key":"R37-2-20210128","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1161\/01.CIR.0000033222.75187.B9","article-title":"Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women.","volume":"106","author":"Blake","year":"2002","journal-title":"Circulation"},{"key":"R38-2-20210128","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1093\/clinchem\/44.11.2301","article-title":"Lipoprotein(a) as a risk factor for ischemic heart disease: meta-analysis of prospective studies.","volume":"44","author":"Craig","year":"1998","journal-title":"Clin Chem"},{"key":"R39-2-20210128","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1161\/01.CIR.102.10.1082","article-title":"Lipoprotein(a) and coronary heart disease: meta-analysis of prospective studies.","volume":"102","author":"Danesh","year":"2000","journal-title":"Circulation"},{"key":"R40-2-20210128","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1161\/01.CIR.98.8.731","article-title":"Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women.","volume":"98","author":"Ridker","year":"1998","journal-title":"Circulation"},{"key":"R41-2-20210128","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/j.jacc.2005.02.080","article-title":"Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol 70 mg\/dl and C-reactive protein 2 mg\/l: an analysis of the PROVE-IT TIMI-22 trial.","volume":"45","author":"Ridker","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"R42-2-20210128","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1161\/01.CIR.0000052939.59093.45","article-title":"Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association.","volume":"107","author":"Pearson","year":"2003","journal-title":"Circulation"},{"key":"R43-2-20210128","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1161\/01.CIR.0000053730.47739.3C","article-title":"Clinical application of C-reactive protein for cardiovascular disease detection and prevention.","volume":"107","author":"Ridker","year":"2003","journal-title":"Circulation"},{"key":"R44-2-20210128","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1161\/01.CIR.0000100688.17280.E6","article-title":"Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial.","volume":"108","author":"Ridker","year":"2003","journal-title":"Circulation"},{"key":"R45-2-20210128","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.amjcard.2005.04.019","article-title":"Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations.","volume":"96","author":"Davidson","year":"2005","journal-title":"Am J Cardiol"},{"key":"R46-2-20210128","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1161\/CIRCULATIONAHA.106.180945","article-title":"Core components of cardiac rehabilitation\/secondary prevention programs: 2007 update: a scientific statement from the American Heart Association Exercise, Cardiac Rehabilitation, and Prevention Committee, the Council on Clinical Cardiology; the Councils on Cardiovascular Nursing, Epidemiology and Prevention, and Nutrition, Physical Activity, and Metabolism; and the American Association of Cardiovascular and Pulmonary Rehabilitation.","volume":"115","author":"Balady","year":"2007","journal-title":"Circulation"},{"key":"R47-2-20210128","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/j.amjcard.2006.12.063","article-title":"Effect of coenzyme q10 on myopathic symptoms in patients treated with statins.","volume":"99","author":"Caso","year":"2007","journal-title":"Am J Cardiol"},{"key":"R48-2-20210128","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.clinthera.2006.01.005","article-title":"Statin-related adverse events: a meta-analysis.","volume":"28","author":"Silva","year":"2006","journal-title":"Clin Ther"},{"issue":"11A","key":"R49-2-20210128","doi-asserted-by":"crossref","first-page":"3C","DOI":"10.1016\/j.amjcard.2004.02.006","article-title":"Emerging therapeutic strategies for the management of dyslipidemia in patients with the metabolic syndrome.","volume":"93","author":"Davidson","year":"2004","journal-title":"Am J Cardiol"},{"key":"R51-2-20210128","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1056\/NEJMoa0800742","article-title":"Simvastatin with or without ezetimibe in familial hypercholesterolemia.","volume":"358","author":"Kastelein","year":"2008","journal-title":"N Engl J Med"},{"key":"R52-2-20210128","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJM199011083231901","article-title":"Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B.","volume":"323","author":"Brown","year":"1990","journal-title":"N Engl J Med"},{"key":"R53-2-20210128","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1001\/archinte.159.16.1893","article-title":"Colesevelam hydrochloride (Cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects.","volume":"159","author":"Davidson","year":"1999","journal-title":"Arch Intern Med"},{"key":"R54-2-20210128","doi-asserted-by":"crossref","first-page":"74U","DOI":"10.1016\/S0002-9149(98)00731-0","article-title":"Efficacy and safety of an extended-release niacin (Niaspan): a long-term study.","volume":"82","author":"Capuzzi","year":"1998","journal-title":"Am J Cardiol"},{"issue":"suppl 1","key":"R55-2-20210128","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1007\/BF03216290","article-title":"Coronary Drug Project: experience with niacin. Coronary Drug Project Research Group.","volume":"40","author":"Berge","year":"1991","journal-title":"Eur J Clin Pharmacol"},{"key":"R56-2-20210128","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.0954-6820.1988.tb15891.x","article-title":"Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid.","volume":"223","author":"Carlson","year":"1988","journal-title":"Acta Med Scand"},{"key":"R57-2-20210128","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa011090","article-title":"Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.","volume":"345","author":"Brown","year":"2001","journal-title":"N Engl J Med"},{"issue":"4","key":"R58-2-20210128","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.amjcard.2004.10.012","article-title":"Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial).","volume":"95","author":"Grundy","year":"2005","journal-title":"Am J Cardiol"},{"key":"R59-2-20210128","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/clc.4960290609","article-title":"Effects of fenofibrate on atherogenic dyslipidemia in hypertriglyceridemic subjects.","volume":"29","author":"Davidson","year":"2006","journal-title":"Clin Cardiol"},{"key":"R60-2-20210128","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.","volume":"341","author":"Rubins","year":"1999","journal-title":"N Engl J Med"},{"issue":"9600","key":"R61-2-20210128","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(07)61607-9","article-title":"Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial.","volume":"370","author":"Keech","year":"2007","journal-title":"Lancet"},{"issue":"12A","key":"R62-2-20210128","doi-asserted-by":"crossref","first-page":"4i","DOI":"10.1016\/j.amjcard.2007.03.002","article-title":"Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.","volume":"99","author":"Goff","year":"2007","journal-title":"Am J Cardiol"},{"key":"R63-2-20210128","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.clinthera.2007.07.018","article-title":"Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g\/d to simvastatin 40 mg\/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.","volume":"29","author":"Davidson","year":"2007","journal-title":"Clin Ther"},{"issue":"9177","key":"R64-2-20210128","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(99)07072-5","article-title":"3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nellInfarto miocardico.","volume":"354","year":"1999","journal-title":"Lancet"}],"container-title":["Journal of Cardiopulmonary Rehabilitation and Prevention"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/HCR.0b013e318192754e","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:59:23Z","timestamp":1620953963000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01273116-200901000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/hcr.0b013e318192754e","relation":{},"ISSN":["1932-7501"],"issn-type":[{"value":"1932-7501","type":"print"}],"subject":[],"published":{"date-parts":[[2009,1]]}}}